ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 587,29
-0,60%
Dow Jones
40 211,72
0,53%
DAX
18 515,72
-0,45%
Brent Oil
83,655
-0,81%
Bitcoin
63 249,07
-2,47%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
06/05/200822h30Business WireAllos Therapeutics to Present at the Bank of America 2008 Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/200820h24Edgar (US Regulatory)Allos Therapeutics Inc - Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/04/200822h00Business WireAllos Therapeutics to Report 2008 First Quarter Financial Results on May 7, 2008NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/04/200814h31Edgar (US Regulatory)Allos Therapeutics Inc - Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/04/200814h00Business WireAllos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell LymphoNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/03/200823h06Edgar (US Regulatory)Allos Therapeutics Inc - Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/02/200822h54Edgar (US Regulatory)Allos Therapeutics Inc - Annual Report (10-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/02/200813h30Business WireAllos Therapeutics Reports 2007 ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/02/200821h52Edgar (US Regulatory)Allos Therapeutics Inc - Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/02/200816h54Edgar (US Regulatory)Allos Therapeutics Inc - Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/02/200814h00Business WireAllos Therapeutics to Report 2007 Results on February 27, 2008NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/02/200821h23Edgar (US Regulatory)Allos Therapeutics Inc - Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/01/200814h00PR Newswire (US)Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/01/200814h00PR Newswire (US)Allos Therapeutics Appoints Bruce K. Bennett as Vice President, ManufacturingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/01/200814h00PR Newswire (US)Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/12/200714h00PR Newswire (US)Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with PeriphNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200714h00PR Newswire (US)Allos Therapeutics to Present at the 2008 JPMorgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/200714h00PR Newswire (US)Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/11/200714h00PR Newswire (US)Allos Therapeutics to Present at the 2007 BMO Capital Markets Focus on Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/11/200714h00PR Newswire (US)Allos Therapeutics to Present at the 2007 Lazard Capital Markets Healthcare Investor ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/11/200722h00PR Newswire (US)Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/11/200722h00PR Newswire (US)Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/11/200720h02Edgar (US Regulatory)Allos Therapeutics Inc - Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/11/200713h30PR Newswire (US)Allos Therapeutics Reports Third Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/10/200713h00PR Newswire (US)Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/10/200722h01PR Newswire (US)Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/10/200713h55PR Newswire (US)Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/09/200716h43Edgar (US Regulatory)Allos Therapeutics Inc (Other) (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/09/200721h35Edgar (US Regulatory)Allos Therapeutics Inc (Other) (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/09/200713h30PR Newswire (US)Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in PatientsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
AI
Air Liquide
NASDAQ
AAPL
Apple
EU
PX1
CAC 40
EU
VIV
Vivendi
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
EU
HO
Thales
EU
AF
Air FranceKLM
EU
PX4
SBF 120
EU
EN
Bouygues
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés